All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On May 14, 2020, 177Lu lilotomab satetraxetan received a positive opinion from the European Medicines Agency for an orphan drug designation application for the treatment of marginal zone lymphoma (MZL). The adoption of the positive opinion by the European Commission is expected to occur shortly.1
177Lu lilotomab satetraxetan is a next generation β-particle emitting radioimmunoconjugate that sensitizes and upregulates CD37+ B-cell cancer cells before treatment with CD20 immunotherapy. Particularly, it has been shown to act synergistically with rituximab.2
The positive opinion was based on positive data from the LYMRIT-37-01 phase I/IIa (NCT01796171) trial in patients with relapsed indolent non-Hodgkin lymphoma. In the MZL patient arm (n = 9; heavily pretreated patients with advanced disease), the overall response rate was 78%, and 44% of patients achieved a complete response. Data from this trial were encouraging as a once-only administration of 177Lu lilotomab satetraxetan resulted in the highest response rate of any patient subpopulation in this trial.1
177Lu lilotomab satetraxetan has previously been granted fast-track designation in the US for the treatment of patients with relapsed or refractory follicular lymphoma after ≥ 2 prior systemic therapies.3
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox